Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

here

Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.

Our website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. For additional details, please see our Privacy Policy. Accept

Our website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. For additional details on what cookies are in use, options for accepting cookies, and to review our privacy policy, please view .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information, such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.

Analytics cookies used:

LinkedIn
Twitter
Facebook
Google Tag Manager
GStatic
Google AdWords

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

More information about our Cookie Policy can be found within our Privacy Policy

library

NASH Roundtable